Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Trastuzumab Best Given Along with Chemotherapy

TOP - April 2010 Vol 3, No 2 published on June 10, 2010 in Breast Cancer

For women with human epidermal growth factor receptor type 2 (HER2)-positive early breast cancer, delaying trastuzumab until chemotherapy is completed may impair outcomes, according to findings from the landmark N9831 trial. The findings were presented by Edith Perez, MD, director of the Breast Cancer Program at the Mayo Clinic, Jacksonville, Florida.

The addition of 52 weeks of trastuzumab, either after standard chemotherapy with doxorubicin/cyclophosphamide followed by paclitaxel (AC-T) or concurrently with the paclitaxel, reduced the risk of breast cancer recurrence by 33% overall, but the benefit was significantly greater when trastuzumab was given concurrently with the paclitaxel portion of the chemotherapy, an approach that can now be recommended, Perez said.

"Often, the research community conducts studies that conclude with 'that was interesting, but let's do more research,'" she noted. "This is an important finding on how we can help prevent breast cancer recurrence and improve survival...This will clearly inform physician decision-making."

The N9831 trial, by the North Central Cooperative Trials Group, consisted of two comparisons. The first comparison included 2448 women randomized to chemotherapy alone or chemotherapy followed by trastuzumab. The proportion of women remaining diseasefree increased from 72% with chemotherapy alone to 80% with the addition of trastuzumab. The second comparison, which included 1903 women who were analyzed according to whether they received trastuzumab after chemo therapy (sequentially) or along with chemo therapy (concurrently with paclitaxel), continued for 52 weeks.

The sequential use of trastuzumab reduced recurrences by 33% over chemotherapy alone. At a median follow-up time of 5.3 years, 80% of women receiving 52 weeks of trastuzumab after chemotherapy were alive and disease-free, compared with 72% not receiving trastuzumab. But by giving trastuzumab concurrently with the paclitaxel portion of chemotherapy, the risk of recurrence was reduced by an additional 25%, compared with the sequential delivery of the drug. With concurrent trastuzumab, 84% of women were alive and disease-free compared with 80% of women treated sequentially, Perez reported.

"Based on a positive risk-benefit ratio, we recommend that adjuvant tras tuzumab be incorporated in a concurrent fashion with taxane chemotherapy," she said. 

Related Items
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Breast Cancer
Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Breast Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Updates
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Updates, In the News
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Yvette Florio Lane
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Updates, In the News
Last modified: April 27, 2020